A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity. 1997

M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.

Prion-related encephalopathies are characterized by astrogliosis and nerve cell degeneration and loss. These lesions might be the consequence of an interaction between the abnormal isoform of the cellular prion protein that accumulates in nervous tissue and the plasma membranes. Previously we found that a synthetic peptide, homologous to residues 106-126 of the human prion protein, is fibrillogenic and toxic to neurons and trophic to astrocytes in vitro. This study dealt with the ability of the peptide to interact with membranes. Accordingly, we compared PrP 106-126 with different synthetic PrP peptides (PrP 89-106, PrP 127-147, a peptide with a scrambled sequences of 106-126, and PrP 106-126 amidated at the C-terminus) as to the ability to increase the microviscosity of artificial and natural membranes. The first three had no effect on nerve and glial cells in vitro, whereas the amidated peptide caused neuronal death. Using a fluorescent probe that becomes incorporated into the hydrocarbon core of the lipid bilayer and records the lipid fluidity, we found PrP 106-126 able to increase significantly the membrane microviscosity of liposomes and of all cell lines investigated. This phenomenon was associated with the distribution of the peptide over the cell surface, but not with changes in the membrane lipid or protein content, or with membrane lipid phase transitions. Accordingly, we deduced that increased membrane microviscosity was unrelated to changes in the membrane native components and was the result of increased lipid density following PrP 106-126 embedding into the lipid bilayer. No control peptides had comparable effects on the membrane microviscosity, except PrP 106-126 amidated at the C-terminus. Since the latter was as neurotoxic, but not as fibrillogenic, as PrP 106-126, we argued that the ability of PrP 106-126 to increase membrane microviscosity was unrelated to the propensity of the peptide to raise fibrils. Rather, it could be connected with the primary structure of PrP 106-126, characterized by two opposing regions, one hydrophilic and the other hydrophobic, that enabled the peptide to interact with the lipid bilayer. Based on these findings, we speculated that the glial and nerve cell involvement occurring in prion-related encephalopathies might be caused by the interaction with the plasma membrane of a PrP 106-126-like fragment or of the sequence spanning residues 106-126 of the abnormal isoform of the prion protein.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008051 Lipid Bilayers Layers of lipid molecules which are two molecules thick. Bilayer systems are frequently studied as models of biological membranes. Bilayers, Lipid,Bilayer, Lipid,Lipid Bilayer
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009498 Neurotoxins Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. Alpha-Neurotoxin,Excitatory Neurotoxin,Excitotoxins,Myotoxin,Myotoxins,Neurotoxin,Alpha-Neurotoxins,Excitatory Neurotoxins,Excitotoxin,Alpha Neurotoxin,Alpha Neurotoxins,Neurotoxin, Excitatory,Neurotoxins, Excitatory
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011328 Prions Small proteinaceous infectious particles which resist inactivation by procedures that modify NUCLEIC ACIDS and contain an abnormal isoform of a cellular protein which is a major and necessary component. The abnormal (scrapie) isoform is PrPSc (PRPSC PROTEINS) and the cellular isoform PrPC (PRPC PROTEINS). The primary amino acid sequence of the two isoforms is identical. Human diseases caused by prions include CREUTZFELDT-JAKOB SYNDROME; GERSTMANN-STRAUSSLER SYNDROME; and INSOMNIA, FATAL FAMILIAL. Mink Encephalopathy Virus,Prion,Encephalopathy Virus, Mink
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
January 1997, The Journal of biological chemistry,
M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
June 2009, Journal of neuroscience methods,
M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
June 2015, Neuropharmacology,
M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
September 1996, Glia,
M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
November 1999, The Histochemical journal,
M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
January 1998, Clinical science (London, England : 1979),
M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
January 2011, Topics in current chemistry,
M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
May 2003, Journal of virology,
M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
November 1998, Journal of neuroscience research,
M Salmona, and G Forloni, and L Diomede, and M Algeri, and L De Gioia, and N Angeretti, and G Giaccone, and F Tagliavini, and O Bugiani
January 1998, European journal of cell biology,
Copied contents to your clipboard!